Netherlands· NL-efb4a3d0a44c
Cejemly 600 mg concentraat voor oplossing voor infusie
A sugemalimab product containing sugemalimab, registered in Netherlands by CStone Pharmaceuticals Ireland Limited. The same ATC class is registered in 7 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Sugemalimab is registered in 7 of 19 countries.
Countries holding a registration under ATC L01FF11 (sugemalimab), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 5 of them publish a price we can compare per daily dose
Sugemalimab · ATC L01FF11
7 / 19 countries
- Belgiumprice
- Czechiaprice
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- SUGEMALIMAB
- Manufacturer
- CStone Pharmaceuticals Ireland Limited
- Country
- Netherlands (NL)
- ATC code
- L01FF11
- ATC class
- Sugemalimab
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/24/1833
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Sugemalimab in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumCejemly 600 mgSfl Pharmaceuticals Deutschland
- CzechiaCEJEMLYCStone Pharmaceuticals Ireland Limited, Dublin 1
- SpainCEJEMLY 600 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONCstone Pharmaceuticals Ireland Limited
- FinlandCejemlyCstone Pharmaceuticals Ireland Limited
- IrelandCejemly 600 mg concentrate for solution for infusionCstone Pharmaceuticals Ireland Limited
- IcelandCejemlyCstone Pharmaceuticals Ireland Limited
- PolandCejemlyCStone Pharmaceuticals Ireland Limited
- SwedenCejemly 600 mg Koncentrat till infusionsvätska, lösningCStone Pharmaceuticals Ireland Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Cejemly
- Liechtenstein · Cejemly
- Norway · Cejemly
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/da7111bf-45a3-4fd3-a735-b9c9ae36adf4 GET /v1/drugs/da7111bf-45a3-4fd3-a735-b9c9ae36adf4?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Concentraat voor oplossing voor infusie",
"route": "Intraveneus gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/cejemly-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Sugemalimab",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp131162",
"excipients": [
"HISTIDINE, (L-)",
"HISTIDINEMONOHYDROCHLORIDE 1-WATER (L-)",
"MANNITOL (D-) (E 421)",
"NATRIUMCHLORIDE",
"POLYSORBAAT 80 (E 433)",
"WATER VOOR INJECTIE"
],
"substances": [
"SUGEMALIMAB"
],
"leaflet_url": null,
"authorised_at": "2024/07/24",
"procedure_number": "EMEA/H/C/006088",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/24/1833",
"additional_monitoring": "Y"
}See everything about sugemalimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.